Australian Dry Eye

Click here to edit subtitle

News

view:  full / summary

LO2A Drops Improve Dry Eye Symptoms in Sjögrens Patients, Phase 2 Study Shows

Posted by australiandryeye on June 17, 2018 at 5:55 AM Comments comments (0)

LO2A eye drops significantly improve dry eye symptoms in Sjögren’s syndrome patients, according to a small Phase 2 clinical study performed in Hungary.


The findings were presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, on May 2 in Honolulu, Hawaii, in the poster presentation “The anti-inflammatory effect of isotonic glycerol in Sjögren’s syndrome-related dry eye.”


The reduced tear...

Read Full Post »

Safety, ethical concerns raised over private stem cell dry eye treatment

Posted by australiandryeye on June 17, 2018 at 5:55 AM Comments comments (0)

A private stem cell clinic in Sydney has been charging patients thousands of dollars to treat the symptoms of dry eye disease with procedures described by experts as unproven and potentially dangerous.


The business, Olympus Stem Cells – with sites at Circular Quay, Lane Cove, Rosebery, Mount Druitt and Sydney Olympic Park – is one of 80 such clinics offering autologous stem cell treatments across Australia, however Olympus is the only business that advertises tre...

Read Full Post »

Electric solution for dry eye?

Posted by australiandryeye on June 17, 2018 at 5:50 AM Comments comments (0)

University of Michigan researchers have investigated the potential for a natural voltage boost to alleviate the symptoms of dry eye.


New research, published in Cell Physiology, explored how bioelectrical responses of goblet cells in the eye adapt to fluid imbalance.


In a study of rats, scientists found that electrical activity in the goblet cells increases as hyperosmolarity rises in the tear film, allowing the cells to produce more mucin.


Read Full Post »

Imprimis offshoot raises $20M to develop dry-eye meds

Posted by australiandryeye on May 28, 2018 at 8:05 AM Comments comments (0)

Surface Pharmaceuticals has rung up about $20 million in a sale of series A preferred stock, completing its spinoff from Imprimis Pharmaceuticals into a separately financed and managed company. The money will support Surface’s push for FDA approval of three products in five ocular indications, including dry eye.


Imprimis will maintain an ownership stake of about 30% and retain royalty interests in certain products. Surface’s initial proceeds from venture capital ...

Read Full Post »

Tear Film Innovations raises $8.5M following clearance of its dry eye device

Posted by australiandryeye on May 28, 2018 at 8:05 AM Comments comments (0)

Tear Film Innovations has raised $8.5 million in series B financing as the company plans to bring on additional staff to continue development of its iLux device treatment for evaporative dry eye and related syndromes, including dysfunction of the Meibomian glands found on the rims of eyelids.


The preferred stock funding round was led by Visionary Ventures Fund and Bluestem Capital and completes the capitalization f...

Read Full Post »

Aldeyra Therapeutics Presents Dry Eye Disease Phase 2a Clinical Trial Results at the Association for Research in Vision and Ophthalmology 2018 Annual Meeting

Posted by australiandryeye on May 6, 2018 at 5:10 AM Comments comments (0)

Data Demonstrate Statistically and Clinically Significant Activity of Topical Ocular 0.1% Reproxalap Across a Broad Array of Signs and Symptoms

 

LEXINGTON, Mass., May 1, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, presented the results of a randomized, double-masked, parallel-group Phase 2a dry eye disease c...

Read Full Post »

Sight Sciences launches pivotal trial of TearCare dry-eye disease treatment

Posted by australiandryeye on May 6, 2018 at 5:10 AM Comments comments (0)

Ophthalmic medical device company Sight Sciences today announced the launch of a new pivotal trial exploring the safety and effectiveness of its TearCare system in patients with dry eye disease.


The Menlo Park, Calif.-based company’s TearCare system is a wearable therapeutic eyelid technology designed to deliver energy over a specified period to liquify meibum, an oily coating on the eye’s surface which prevents tear film evaporation.

 

The devic...

Read Full Post »

Sylentis presents clinical study results of new treatment for dry eye syndrome

Posted by australiandryeye on May 4, 2018 at 5:15 AM Comments comments (0)


Sylentis, Pharmaceutical Company belonging to the PharmaMar Group, has presented results from the clinical studies carried out with tivanisiran for the treatment of dry eye syndrome and that has enabled the start-up of the Phase III "Helix" clinical trial. The presentation has taken place within the framework of the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) that has been held from the 29th of April to the 3rd of May in Honolulu, Hawaii.

Read Full Post »

VIDEO: Novaliq seeks entry into US dry eye market

Posted by australiandryeye on April 17, 2018 at 1:20 AM Comments comments (0)

WASHINGTON ― At the Ophthalmology Innovation Summit at ASCRS here, Bernhard Günther, president of Novaliq, discusses the company’s efforts to enter the U.S. market, principally in treating dry eye disease, by establishing an office in Cambridge, Massachusetts.


https://www.healio.com/ophthalmology/ophthalmic-business/news/online/%7B786f9329-28c4-4580-b18f-94083f661da4%7D/video-novaliq-seeks-entry-into-us-dry-eye-market

SiteOne Therapeutics Announces Abstract Presentation At the Association for Research in Vision and Ophthalmology (ARVO)

Posted by australiandryeye on March 27, 2018 at 6:30 AM Comments comments (0)

BOZEMAN, Montana, March 26, 2018 /PRNewswire/ -- SiteOne Therapeutics, Inc., today announced a presentation at the Association for Research in Vision and Opthalmology (ARVO) meeting in Honolulu, Hawaii, April 29 to May 3, 2018.


The abstract will present preclinical research using SiteOne's novel sodium ion channel blockers showing corneal anesthesia, penetration into the ocular structures, and excellent tolerability after topical administration. The study was conducted to ...

Read Full Post »

Biomedical startup AesculaTech is creating a new, more patient-friendly drug delivery system

Posted by australiandryeye on March 26, 2018 at 8:10 AM Comments comments (0)

“Reverse chocolate” — that’s how AesculaTech co-founder and chief science officer Niki Bayat describes the material created by its proprietary technology. Chocolate is solid until heated, when it melts deliciously into liquid. AesculaTech’s material, on the other hand, is a liquid at low temperatures, turns into a gel when heated and then reaches its final, solid state at body temperature. (If you are having a hard time visualizing the process or are distracted b...

Read Full Post »

Grafton Optical to launch new dry eye products

Posted by australiandryeye on March 26, 2018 at 8:05 AM Comments comments (0)

Grafton Optical will launch SBM Sistemi’s Ocular Surface Analyser and the i-Pen Tear Film Osmolarity System by i-Med Pharma at Optrafair (14–16 April, Birmingham NEC).


The i-Pen is a hand-held electronic device designed to detect and indirectly measure the elevated tear film osmolarity levels associated with dry eye disease.


The in-practice screening device can be used for patients presenting with dry eye symptoms, as well as pre and post-surger...

Read Full Post »

TopiVert Publication Highlights the Potential of Narrow Spectrum Kinase Inhibitors in Dry Eye Disease and Supports Successful Clinical Proof-Of-Concept Study with TOP1630

Posted by australiandryeye on March 26, 2018 at 8:05 AM Comments comments (0)

TopiVert Publication Highlights the Potential of Narrow Spectrum Kinase Inhibitors in Dry Eye Disease and Supports Successful Clinical Proof-Of-Concept Study with TOP1630


London, UK, 22 March 2018: TopiVert Pharma Ltd ("TopiVert" or the "Company"), a clinical-stage biotechnology company developing Narrow Spectrum Kinase Inhibitors (NSKIs) as novel, locally-acting medicines for the treatment of chronic inflammatory ocular and gastrointestinal diseases, today announces the pub...

Read Full Post »

Yuyu to start clinical trials on dry eye treatment

Posted by australiandryeye on March 26, 2018 at 8:05 AM Comments comments (0)


Yuyu Pharmaceuticals said Thursday that it has received approval from the Ministry of Food and Drug Safety to go ahead with domestic phase 1 clinical trials for YY-101, a peptide-based dry eye treatment.


 

Dry eye syndrome is a common eye condition, in which the eye surface gets damaged due to insufficient tear production or excessive tear evaporation. The number of patients suffering from the disorder is on the rise because of the increase of computer...

Read Full Post »

Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results

Posted by australiandryeye on March 26, 2018 at 8:00 AM Comments comments (0)

Reported topline results from two Phase 3 clinical trials of KPI-121 0.25% - STRIDE 1 and STRIDE 2 – in patients with dry eye disease.


Achieved statistical significance for the primary sign endpoint of conjunctival hyperemia at Day 15 in the ITT population in both trials.


Achieved statistical significance for the primary symptom endpoint of ocular discomfort severity at Day 15 in the ITT population in STRIDE 1 with a trend towards a treatment effect i...

Read Full Post »

Eyelove, the sequel: Jennifer Aniston reprises her starring role in Shire's dry eye awareness push

Posted by australiandryeye on March 24, 2018 at 8:00 AM Comments comments (0)


Time for more eyelove, and more Jennifer Aniston. Since the Shire disease awareness campaign launched more than a year ago, the eye community told Shire they wanted more Jen. So the pharma obliged, with original celebrity spokesperson Aniston even more front and center in its just-launched “eyelove” creative.


Aniston kicked off the eyelove campaign in fall 2016 in ads, telling the story of h...

Read Full Post »

Novaliq begins phase 2 dry eye trial of NOV03

Posted by australiandryeye on March 24, 2018 at 8:00 AM Comments comments (0)

The first patient has been enrolled in the SEECASE phase 2 trial of NOV03 for the treatment of dry eye disease, Novaliq announced in a press release.

 

The multicenter, randomized, double-masked, saline-controlled study will evaluate the effect of NOV03 at both twice daily and four times a day.

NOV03 is designed to penetrate further into the meibomian glands, potentially dissolving meibomian lipids and helping to improve gland functionality, the release said.


Read Full Post »

Bausch + Lomb Receives FDA Approval of LUMIFY

Posted by australiandryeye on March 24, 2018 at 8:00 AM Comments comments (0)

The Only Over-The-Counter Eye Drop With Low-Dose Brimonidine For The Treatment Of Eye Redness


Clinical Studies Showed 95% Symptom Improvement At One Minute, And Reduced Redness For Up To Eight Hours


LAVAL, Quebec, Dec. 22, 2017 /PRNewswire/ -- Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant"), today announced that the U.S. Food and Drug Adm...

Read Full Post »

Biotech with treatment for chronic dry eye disease tied to diabetes raises seed capital

Posted by australiandryeye on March 24, 2018 at 8:00 AM Comments comments (0)

Biotech startup Ocunova, a spin-out from the Penn State University College of Medicine, has closed a fresh round of seed funding to support clinical trials for a treatment aimed at a chronic dry eye condition related to diabetes.


The treatment enlists a drug already approved by the FDA to manage alcohol and opioid dependence called Naltrexone. The company noted on its website that more than 3 million diabetic patients experience chronic dry eye in the U.S.


...

Read Full Post »

Aldeyra Therapeutics Inks Collaboration Deal with Johnson & Johnson to Develop Anti-inflammatory Therapies

Posted by australiandryeye on March 24, 2018 at 7:55 AM Comments comments (0)

By Mark Terry


Based in Lexington, Massachusetts, Aldeyra Therapeutics just signed a collaboration research deal with Janssen Research & Development, a Johnson & Johnson company.


The companies will work together to develop drugs that sequester pro-inflammatory aldehyde mediators. This is a new class of therapeutic targets. Aldeyra’s lead program is reproxalap, a first-in-class drug candidate that has shown anti-inflammatory activity in four Pha...

Read Full Post »

Rss_feed